RICHMOND, Va., Aug. 8 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq:
INSM), a developer of follow-on biologics and biopharmaceuticals, today
reported results for the second quarter and six-months ended June 30, 2008.
Recent Company Highlights
-- Follow-on Biologics Program
-- Completed clinical trial demonstrating the bioequivalence of INS-19,
the company's recombinant human granulocyte colony stimulating
factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for
the treatment of neutropenia that recorded 2007 sales of
approximately $1 billion;
-- Retained The Honorable Bill Thomas, Former Chairman of the House
Ways and Means Committee from 2001 to 2007, as a strategic advisor
to provide counsel on the Company's efforts to bring follow-on
biologics ("FOB") to U.S. consumers;
-- Retained the services of RBC Capital Markets ("RBC") to act as
Insmed's strategic financial advisor to evaluate and focus the
Company's strategic initiatives.
-- The Phase 2 trial of IPLEX(TM) in Myotonic Muscular Dystrophy
("MMD"), which was initiated in December 2007, has seen a strong
patient and physician interest and is now fully enrolled;
-- Received $2.6 million in cost recovery revenue in the second quarter
related to the expanded access program ("EAP") for IPLEX(TM). The
EAP in Italy to treat patients with Amyotrophic Lateral Sclerosis
("ALS"), also known as Lou Gehrig's Disease, currently includes 22
physicians and approximately 100 subjects have enrolled.
"Over the past several months, Insmed has achieved several important
milestones across the full spectrum of its business," said Geoff Allan,
President and CEO of Insmed. "Most importantly, our FOB initiatives have
received strong scientific validati
|SOURCE Insmed Inc.|
Copyright©2008 PR Newswire.
All rights reserved